Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
Acrivon Therapeutics announced it will present data at the AACR D3 Conference highlighting its AP3 platform and the Phase 1/2 clinical results for ACR-2316, a WEE1/PKMYT1 inhibitor. Early clinical observations show partial responses and durable benefit in small cell lung cancer and non-small cell lung cancer subtypes, tumor types not previously shown to be sensitive to this class of inhibitors.
Key figures
- Drug Name
- ACR-2316
- Phase Of Trial
- Phase 1/2
- Target
- WEE1/PKMYT1
- Dosing regimen
- two weekly, oral dosing regimens established
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.